chr2-218814188-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000784.4(CYP27A1):c.1184+1G>A variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000128 in 1,614,128 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000784.4 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP27A1 | NM_000784.4 | c.1184+1G>A | splice_donor_variant | ENST00000258415.9 | NP_000775.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP27A1 | ENST00000258415.9 | c.1184+1G>A | splice_donor_variant | 1 | NM_000784.4 | ENSP00000258415 | P1 | |||
CYP27A1 | ENST00000494263.5 | n.1619G>A | non_coding_transcript_exon_variant | 6/7 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152254Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000159 AC: 40AN: 251280Hom.: 0 AF XY: 0.000214 AC XY: 29AN XY: 135822
GnomAD4 exome AF: 0.000132 AC: 193AN: 1461874Hom.: 0 Cov.: 31 AF XY: 0.000165 AC XY: 120AN XY: 727238
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152254Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74390
ClinVar
Submissions by phenotype
Cholestanol storage disease Pathogenic:11
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change affects a donor splice site in intron 6 of the CYP27A1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs587778777, gnomAD 0.07%). Disruption of this splice site has been observed in individuals with cerebrotendinous xanthomatosis (PMID: 9392430, 21645175, 28894950). This variant is also known as In6+1G>A. ClinVar contains an entry for this variant (Variation ID: 65833). Studies have shown that disruption of this splice site results in skipping of 89 nucleotides of exon 6 and introduces a premature termination codon (PMID: 9392430). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | curation | GeneReviews | Aug 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 26, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 20, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | May 20, 2023 | The observed invariant splice acceptor variant c.1184+1G>A in CYP27A1 gene has been reported previously in both homozygous and compound heterozygous state in multiple inviduals affected with cerebrotendinous xanthomatosis (Ginanneschi et al. 2013; Rashvand et al. 2021). Experimental evidence shows that this variant activates a cryptic donor splice site and leads to skipping of 89 base pairs of exon 6, introduces a new reading frame and creates a premature stop codon that does not three essential amino acids (Lys354, Lys358, and Arg362) that are important for the ferredoxin-binding domain (Rashvand et al. 2021). The c.1184+1G>A variant is present with an allele frequency of 0.02% on gnomAD Exomes database. This variant has been submitted to the ClinVar database as Likely Pathogenic / Pathogenic (multiple submissions). SpliceAI predicts a splice donor loss of 0.99 for this variant. Loss of function variants in CYP27A1 gene have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic. In the absence of another reportable variant in the CYP27A1 gene, the molecular diagnosis is not confirmed. - |
Pathogenic, criteria provided, single submitter | clinical testing | Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 13, 2022 | Variant summary: CYP27A1 c.1184+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes the canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing by skipping of exon 7 and joining exon 6 to exon 8 that translates to a sequence of 28 novel amino acids preceding a termination codon (Garuti_1996). The variant allele was found at a frequency of 0.00016 in 251280 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CYP27A1 causing Cerebrotendinous Xanthomatosis (0.00016 vs 0.0011), allowing no conclusion about variant significance. c.1184+1G>A has been reported in the literature as homozygous and compound heterozygous genotypes in multiple individuals affected with Cerebrotendinous Xanthomatosis (example, Garuti_1996, Gianneschi_2013). These data indicate that the variant is very likely to be associated with disease. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Oct 20, 2021 | NM_000784.3(CYP27A1):c.1184+1G>A is a canonical splice variant classified as pathogenic in the context of cerebrotendinous xanthomatosis. c.1184+1G>A has been observed in cases with relevant disease (PMID: 22878431). Functional assessments of this variant are available in the literature (PMID: 9392430). c.1184+1G>A has been observed in population frequency databases (gnomAD: SAS 0.07%). In summary, NM_000784.3(CYP27A1):c.1184+1G>A is a canonical splice variant in a gene where loss of function is a known mechanism of disease, is predicted to disrupt protein function, and has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 28, 2022 | - - |
not provided Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 09, 2022 | Observed in the homozygous state or with a pathogenic variant on the opposite allele (in trans) in patients with cerebrotendinous xanthomatosis referred for genetic testing at GeneDx and in published literature (Garuti et al., 1997; Verrips et al., 2000; Lee et al., 2001; Lipinski et al., 2020); Canonical splice site variant and published functional studies demonstrate that this variant leads to the production of three abnormal transcripts, and almost undetectable levels of mRNA in patient fibroblasts (Garuti et al., 1997); This variant is associated with the following publications: (PMID: 10775536, 25525159, 11181744, 26643207, 20402754, 28894950, 29260356, 32793533, 33659184, 34066437, 33400472, 31589614, 33083013, 33520900, 9392430) - |
Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 10, 2017 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | May 05, 2023 | PP3, PM3, PS3, PS4, PVS1 - |
CYP27A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 02, 2024 | The CYP27A1 c.1184+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported in the homozygous and compound heterozygous states in individuals with cerebrotendinous xanthomatosis (see for example Garuti et al. 1997. PubMed ID: 9392430; Lipiński et al. 2020. PubMed ID: 32793533). This variant is reported in 0.072% of alleles in individuals of South Asian descent in gnomAD. Variants that disrupt the consensus splice donor site in CYP27A1 are expected to be pathogenic, and this variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/65833). Given all the evidence, we interpret c.1184+1G>A as pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2022 | The c.1184+1G>A intronic alteration consists of a G to A substitution one nucleotide after coding exon 6 of the CYP27A1 gene. Alterations that disrupt the canonical splice donor site are typically deleterious in nature (Richards, 2015). Based on data from gnomAD, the A allele has an overall frequency of 0.02% (46/282682) total alleles studied. The highest observed frequency was 0.07% (22/30614) of South Asian alleles. This alteration has been detected in the homozygous state and in trans with other disease-causing CYP27A1 alterations in multiple unrelated individuals diagnosed with cerebrotendinous xanthomatosis (Stelten, 2018; Lipiski, 2020; Lipiski, 2020; Rashvand, 2021; Ginanneschi, 2013; Lee, 2001). This nucleotide position is highly conserved in available vertebrate species. Experimental studies show this alteration results in abnormal splicing and introduces a frameshift (Garuti, 1997). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at